[This page is intended to provide a study summary, the sections of which are below. Please complete these sections, as applicable. The headings below are suggested headings. You can remove inapplicable sections, or add new ones relevant to your study]
Investigator Names and Contact Information
Pinkal Desai MD MPH [firstname.lastname@example.org]
Myeloid Leukemia (AML) is the most common acute leukemia in adults, with an annual
incidence of approximately 13,000 cases. The median age at presentation is 66
years and the prognosis is generally poor, with 40-50% five-year survival for
patients <60 years and less than 10% survival for patients ≥ 60 years.
Historically, age and cytogenetics have been the most important determinants of
prognosis. Over the last few years, next generation sequencing technologies
have revealed that AML is a molecularly heterogeneous disease characterized by
the accumulation of somatic mutations that occur early in leukemogenesis. In
some patients, pre-leukemic mutations may be present and potentially detectable
in the peripheral blood before the onset of overt disease. The objectives of
this proposal are: 1. To compare the frequency of clonal, preleukemic mutations
in the peripheral blood of patients with AML taken prior to the development of
overt disease with age matched controls; 2. To investigate the frequency,
repertoire and evolution of somatic mutations as well as baseline hematologic
parameters in peripheral blood specimens taken from patients with
pathologically confirmed AML prior to the development of overt leukemia; and 3.
To assess possible correlations between the nature, timing and pattern of
specific pre-leukemic mutations and development of AML. Targeted sequencing using DNA
(1 µg) from peripheral blood samples obtained prior to the development of AML
will be performed on 229 pathologically confirmed cases and 200 age matched controls
from both CT and OS participants using a 200 gene panel on an Illumina
platform. In some cases, several blood specimens are available for sequencing
for participants prior to disease development. It is expected that this work will result in unprecedented
insights into the ontogeny and pathogenesis of AML. The data may pave the way
for novel strategies in early treatment and prevention of AML.
To compare the mutations identified using a 200 gene panel on DNA from banked peripheral blood specimens from women taken prior to their diagnosis of acute myeloid leukemia (AML) with those identified in age-matched controls.
To compare the time to development of overt disease in AML patients with precursor mutations identified by a 200 gene panel, with those patients who did not have pre-disease clonal hematopoiesis.
To study the evolution of clonal changes in the banked peripheral blood of women who underwent serial monitoring and had multiple specimens prior to their subsequent diagnosis of AML (if available).
To assess possible correlations between the baseline hematological parameters as well as nature, timing and pattern of specific pre-leukemic mutations and the development of AML.
To compare the metabolic (2 hydroxyglutarate, vitamin C, glucose) and inflammatory risk factors (inflammatory chemokine panel and bacterial translocation) in plasma that modify the relationship of mutations in IDH, TP53, DNMT3A and TET2 as identified in the proposal and risk of AML. ( requesting plasma samples)
To compare the DNA methylation pattern and telomere length between cases and controls using left over DNA samples to understand the functional genomic state associated with the preleukemic mutations. ( left over samples)